Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma

Jithma P. Abeykoon, Julia Vaxman, Sanjay V. Patel, Shaji Kumar, Gabriella C. Malave, Kimberly S. Young, Sikander Ailawadhi, Jeremy T. Larsen, Angela Dispenzieri, Eli Muchtar, Wilson I. Gonsalves, Taxiarchis Kourelis, Nelson Leung, Rahma Warsame, Ronald S. Go, Leif Bergsagel, Martha Q. Lacy, S. Vincent Rajkumar, Morie A. Gertz, Prashant Kapoor

Research output: Contribution to journalArticlepeer-review

Abstract

Belantamab mafodotin (BLMF) is a B-cell maturation antigen-directed antibody-drug conjugate, recently approved for advanced multiple myeloma (MM). The impact of BLMF-induced ocular toxicity on patient outcomes is unknown. We studied a cohort of 38 consecutively seen patients treated with BLMF outside of trials. Of those, 75% experienced ocular toxicity, with 69% developing keratopathy. Among patients requiring ocular toxicity-related permanent BLMF discontinuation (14%) or dose reduction (11%), 70% had progression of MM within a median of 3 months (95% confidence interval: 0.2–not reached) following BLMF interruption or dose reduction. Ocular toxicity is a major deterrent to the continuous use of BLMF in routine clinical practice. Measures to successfully prevent and mitigate ocular toxicity should be developed to achieve the full potential of this agent.

Original languageEnglish (US)
JournalBritish journal of haematology
DOIs
StateAccepted/In press - 2022

Keywords

  • antibody-drug conjugate
  • B-cell maturation antigen
  • monoclonal gammopathy

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma'. Together they form a unique fingerprint.

Cite this